The present invention relates to the use of one or more treatment modalities in the cosmetic treatment of human mucosal tissue to provide, among other things, vaginal and anal tightening and urinary incontinence treatment.
Vaginal Relaxation Syndrome (VRS) commonly called “loose vagina” is a quite common medical condition described as a loss of the optimal vaginal structure and is usually associated with vaginal child delivery and natural aging.
Multiple pregnancies and deliveries contribute to a worsening of the VSR condition, as well as the beginning of menopause, which causes a decline in hormone levels and vaginal atrophy.
Most women and their husbands or partners refer to VSR as “loose vagina”, complaining of a loss of vaginal tightness, which is directly related to the reduction of friction during intercourse and thus to a decrease or loss of sexual gratification.
There is a large spectrum of various VRS treatment options on the market ranging from behavioral (Kegel exercises) through pharmacological therapies (hormonal, tightening creams and sprays) to various more-or-less invasive surgical procedures.
While behavioral and pharmacological therapies are noninvasive and safe, they have limited efficacy.
On the other hand, various surgical procedures promise a much better final result at the price of higher associated risks.
Surgical procedures require the cutting and rearrangement of vaginal and peripheral tissue in order to reduce the size of the vaginal canal.
Operating on or near sensitive vaginal tissue is inherently risky and can cause scarring, nerve damage and decreased sensation. Furthermore, patients require an extended recovery period.
The most popular among the surgical procedures are those performed with lasers, where the laser is used instead of scalpel.
Thus there is a clear need for efficient noninvasive solutions for vaginal rejuvenation.
Numerous techniques have been described for tissue rejuvenation mostly for skin treatment. For example, U.S. Pat. No. 6,387,089 describes a procedure referred to as photo rejuvenation, wherein pulsed light is used for heating and shrinking the collagen and thereby restoring the elasticity of the skin. Since collagen is located in the dermis, lasers that target collagen must penetrate through the epidermis and through the dermal epidermal junction. Due to Bier's Law of absorption, the laser beam is typically most intense at the surface of the skin. This results in unacceptable heating of the upper layers of the skin. Various approaches have been described to cool the upper layers of the skin while maintaining the layers underneath at the desired temperature. One approach is to spray a cryogen material on the surface so that the surface remains cool while the underlying layers (and hence collagen) are heated. Such an approach is described in U.S. Pat. No. 6,514,244. Another approach, described in U.S. Pat. No. 6,387,089, is the use of a cooled transparent substance, such as ice, gel or a crystal that is in contact with the surface of the skin. The transparent nature of the coolant allows the laser beam to penetrate the different skin layers while maintaining an acceptable temperature level on the surface of the skin.
An objective of non-ablative photo-rejuvenation is to induce a thermal wound repair response in the papillary and upper reticular dermal compartments (approximately 100-400 micro-meter below the surface of the skin) while sparing the epidermal compartment.
To overcome some of the problems associated with the undesired heating of the upper layers of the skin (epidermal and dermal) described above, U.S. Pat. No. 6,311,090 describes using RF energy and an arrangement comprising RF electrodes that rest on the surface of the skin. A reverse thermal gradient is created that apparently does not substantially affect melanocytes and other epithelial cells. However, even such noninvasive methods have the significant limitation in that energy cannot be effectively focused in a specific region of interest for example the dermis.
Other approaches have been described to heat the dermis without heating more superficial layers. These involve using electrically conductive needles that penetrate the surface of the skin into the tissue and provide heating. U.S. Pat. Nos. 6,277,116 and 6,920,883 describe such systems. Unfortunately, such an approach results in widespread heating of the subcutaneous layer and potentially melting the fat in the subcutaneous layer. This leads to undesired scarring of the tissue.
One approach that has been described to limit the general, uniform heating of the tissue is fractional treatment of the tissue, as described in U.S. Patent Application publication No. 2005/0049582. This application describes the use of laser energy to create treatment zones of desired shapes in the skin, where untreated, healthy tissue lies between the regions of treated tissue. This enables the untreated tissue to undergo a healing and recovery process.
As opposed to traditional laser resurfacing, which treats the whole surface of the target tissue, fractional laser skin resurfacing uses fractional Photothermolysis. It targets tissue with a pattern of dispersed spots. This results in a pattern of microscopic zones of tissue coagulation that heal over several weeks while the skin retains normal appearance. Rather than creating a global tissue effect at the surface of the target tissue, or in the dermis alone, this method creates injury in a small fraction of the skin treated, coagulating multiple columns of tissue, generally 70-100 micron in diameter, extending through the epidermis and deep into the dermis reaching up to generally 1 mm depth. These laser columns create micro thermal zones of tissue coagulation which is surrounded by healthy tissue. The healthy tissue provides a generous reservoir of stem cells and melanocytes in the papillary dermis that are spared from wounding and accelerate the healing process. The small size of the wounds and the short migratory paths for keratinocytes from the spared tissue result in rapid re-epitheliazation and fast epidermal repair. Zones of collagen denaturation in the dermis cause upregulation of the inflammatory cascade, which leads to collagen remodeling to depths of generally 400-700 microns resulting in skin tightening. The fact that patients do not have open wounds leads to minimal downtime. Fractional laser resurfacing is therefore a non-ablative procedure. It offers improved skin texture, tone, pigmentation, fine lines and skin tightening Fractional resurfacing requires a series of 3-5 treatments as opposed to ablative lasers that require a single treatment.
Fractional vaginal rejuvenation systems exist in the market using CO2 or Er:YAG lasers. These include, for example, IntimaLase by Fotona—a minimally-invasive, non-ablative Er:YAG laser vaginal tightening procedure utilizing photothermal laser-mucosa tissue interaction. Another device is FemiLift by Alma Laser. This is a noninvasive Laser Vaginal Tightening device using CO2 laser by thermal heating of the vaginal tissue inner layers inducing collagen and elastin contraction and regeneration of the proteins over time.
Disadvantages of such known fractional laser resurfacing systems include: they are cumbersome and expensive. As well, in order to achieve dramatic results heating of the tissue reaches the temperature in the necrotic zone which is around 70° C., and the tissue, whether it is made up primarily of cells, keratinocytes and their derivatives or collagen, is necrosed or denatured, respectively. Temperatures in the tissue above 100° C. may cause steam to form in the tissue, which may cause disruptive effects. Such temperatures may result in undesirable side effects such as pain, erythema, swelling, occasional scarring, extended healing times and infection.
Thus there is an unmet need for a simple, inexpensive fractional treatment of the vagina that causes tissue injury and triggers tissue healing processes but without the risks and complications caused by tissue heating that creates denaturation and coagulation of tissue. While the present invention may be administered within the confines of a physician's or other operator's office environment, it is of sufficiently simple operation that it may be used in the privacy of the user's home. For example, the present invention may have a switch or other device so that the EMS function may be separable from the RF function so that a user can activate the EMS portion of the present apparatus without activating the RF function for training and/or vaginal tightening purposes.
In an aspect, a device which provides fractional treatment of a body orifice includes a source of fractionated energy; a source of electrical muscle (EMS) energy; a programmed controller to control the application of fractionated and/or EMS energy; a probe for insertion of its distal end into the body orifice. The source of fractionated energy is positioned for transmitting fractionated energy from the source of fractionated energy through the probe to tissue in the vicinity around the body orifice; and, the source of EMS is positioned for transmitting EMS energy from the source of EMS energy through the probe to tissue in the vicinity around the body orifice; the programmed controller is configured to control the activation of fractionated energy and EMS energy one of simultaneously or sequentially.
In another aspect, the body orifice may be selected from one of: a vaginal cavity; an anal cavity, the oral cavity or the aural cavity, and the treatment provides one of vaginal or anal tightening.
In a further aspect, the fractionated energy is radio frequency (RF) energy or Ultrasound (US) energy or it may be light energy.
In yet another aspect, the controller may be configured to activate the EMS energy first, followed by activation of the RF energy, whereby the tissue in the vicinity of the body orifice is first drawn into contact with the probe, followed by activation of RF energy. The controller may activate the application of EMS energy and then RF energy a selected number of times.
In a further aspect, the source of fractionated energy may include electrodes mounted on an outer surface of the probe and may be mounted in the form of one or more spirals along the other surface of the probe. The device may be for home use.
In yet another aspect, a method is providing for the fractional treatment of a body orifice and includes: transmitting fractionated energy from a source of fractionated energy through a probe inserted in the body orifice to tissue in the vicinity around the body orifice; and, transmitting EMS energy from a source of EMS energy through the probe to tissue in the vicinity around the body orifice.
In yet a further aspect, a programmed controller is configured to control the transmitting of the one or more of fractionated and EMS energy one of simultaneously or sequentially. The controller may activate the EMS energy first, followed by activation of the RF energy, whereby the tissue in the vicinity of the body orifice is first drawn into contact with the probe, followed by activation of RF energy. The controller may activate the application of EMS energy and then RF energy a selected number of times. The method may be practiced in one of an office or a home use.
In another aspect, the programmed controller may be configured to control the activation of fractionated energy and/or the EMS energy. The EMS energy may be activated and the fractionated energy source not activated for purposes of tightening the body orifice, including vaginal or anal tightening.
One aspect of the present invention is providing a system and method of treatment for vaginal tightening. The system, shown in
Referring now to
Back to the pulse sequence in
RF may be bipolar or monopolar. In a monopolar configuration, an external electrode on the pubis or lower back may be used. EMS signals may use a dedicated electrode or the same electrodes used for the RF unit. In such a case, a diode bridge known to those skilled in the art may be provided to “cut” the AC RF signals to produce an effective DC signal in the range of 1 to 30 milliseconds. This configuration makes the whole system much simpler and easier to implement as a home-use device. The DC EMS signal may cause the muscle to be smoothed out which in turn may induce contraction.
According to one aspect of the invention, the system is configured to switch between EMS and RF signals. An EMS signal followed by a RF treatment signal may create thermal damage to the adjacent vaginal tissue and cause its tightening According to another embodiment of the present invention, RF only or EMS only signal may be used in order to heat or exercise the vagina respectively. According to yet another embodiment of the present invention, the order of the application of RF and EMS pulses may be in any order or sequence desired to achieve desirable treatment results.
The vagina is a hollow organ and is comprised of a smooth muscle. Smooth muscles are characterized by high elasticity which gives them the ability to stretch while still maintaining strong contractability. Smooth muscle cell cytoplasm is rich with myosin and actin molecules which provide a smooth muscle cell the ability to contract. Tensile structure between smooth muscle cells contains actin filaments of contractile units which are attached to dense bodies creating a network of contracting fibers. This network is neither in a parallel line orientation across nor along the vagina smooth muscle, rather in a more diagonal orientation. As a result, smooth muscle tends to contract in a spirally. Therefore, the most effective way to induce a stimulation of a smooth muscle may not be by providing parallel electrodes 102 along or across a prior art vaginal probe 100 shown in
Turning now to
As mentioned above, it is known to provide light-based vaginal rejuvenation treatments. However, what is not believed to be known is the combination of EM treatment combined with EMS treatment, so that the tissue surrounding the inserted probe will be drawn into contact with the probe in order to provide more effective and efficient treatment of the vaginal walls due to the close contact with the probe and thus the source of energy.
The present application is related to, claims priority to and is a continuation in part of U.S. application Ser. No. 13/510,062, filed May 16, 2012, which is a 371 national phase application of PCT/IL10/00947, filed Nov. 16, 2010, which claims priority to U.S. Provisional Application Ser. No. 61/261,381, filed Nov. 16, 2009, the entirety of which are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
2444173 | St. Pierre | Jun 1948 | A |
3297024 | Robinson | Jan 1967 | A |
4702732 | Powers et al. | Oct 1987 | A |
5169398 | Glaros | Dec 1992 | A |
5296683 | Burkett et al. | Mar 1994 | A |
5419344 | DeWitt | May 1995 | A |
5476504 | Paolizzi | Dec 1995 | A |
5562706 | Lauterbach | Oct 1996 | A |
5755753 | Knowlton | May 1998 | A |
5797904 | Smith | Aug 1998 | A |
5797966 | Bontoux | Aug 1998 | A |
5961475 | Guity | Oct 1999 | A |
6139545 | Utely | Oct 2000 | A |
6273884 | Altshuler et al. | Aug 2001 | B1 |
6277116 | Utely | Aug 2001 | B1 |
6296683 | Kochman et al. | Oct 2001 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6546934 | Ingle et al. | Apr 2003 | B1 |
6692490 | Edwards | Feb 2004 | B1 |
6840954 | Dietz et al. | Jan 2005 | B2 |
7953500 | Bingham et al. | May 2011 | B2 |
9596920 | Shalev et al. | Mar 2017 | B2 |
20010014815 | Matsumura et al. | Aug 2001 | A1 |
20020032441 | Ingle | Mar 2002 | A1 |
20020120260 | Morris et al. | Aug 2002 | A1 |
20030032950 | Altshuler | Feb 2003 | A1 |
20030187488 | Kreindel | Oct 2003 | A1 |
20040019350 | O'Brien | Jan 2004 | A1 |
20040073079 | Altshuler | Apr 2004 | A1 |
20040220622 | Bernabei | Nov 2004 | A1 |
20050015085 | McClurken et al. | Jan 2005 | A1 |
20050107832 | Bernabei | May 2005 | A1 |
20050154433 | Levy, Jr. | Jul 2005 | A1 |
20050171583 | Mosher | Aug 2005 | A1 |
20050222565 | Manstein | Oct 2005 | A1 |
20060036300 | Kreindel | Feb 2006 | A1 |
20060205996 | Presthus | Sep 2006 | A1 |
20060206103 | Altshuler | Sep 2006 | A1 |
20060206110 | Knowlton et al. | Sep 2006 | A1 |
20060217704 | Cockburn et al. | Sep 2006 | A1 |
20070055154 | Torbati | Mar 2007 | A1 |
20070055180 | Deem | Mar 2007 | A1 |
20070060989 | Deem | Mar 2007 | A1 |
20070179490 | Azar | Aug 2007 | A1 |
20070198004 | Altshuler | Aug 2007 | A1 |
20070232966 | Applebaum et al. | Oct 2007 | A1 |
20080039914 | Cory | Feb 2008 | A1 |
20080103565 | Altshuler et al. | May 2008 | A1 |
20080215039 | Slatkine | Sep 2008 | A1 |
20080312646 | Peterson | Dec 2008 | A9 |
20080312648 | Peterson | Dec 2008 | A1 |
20090043293 | Pankratov | Feb 2009 | A1 |
20090156958 | Mehta et al. | Jun 2009 | A1 |
20090270963 | Pelger | Oct 2009 | A1 |
20100016850 | Ron Edoute | Jan 2010 | A1 |
20100049186 | Ingle et al. | Feb 2010 | A1 |
20100057149 | Fahey | Mar 2010 | A1 |
20100174137 | Shim | Jul 2010 | A1 |
20100228304 | Kriksunov et al. | Sep 2010 | A1 |
20110009692 | Gross | Jan 2011 | A1 |
20110130618 | Ron Edoute | Jun 2011 | A1 |
20110224665 | Crosby et al. | Sep 2011 | A1 |
20110230931 | Hagege | Sep 2011 | A1 |
20120215141 | Peddicord | Aug 2012 | A1 |
20120027120 | Shalev et al. | Oct 2012 | A1 |
20120271206 | Shalev et al. | Oct 2012 | A1 |
20130018222 | Miroshnichenko | Jan 2013 | A1 |
20150164401 | Toth | Jun 2015 | A1 |
20150297908 | Alinsod | Oct 2015 | A1 |
20160121112 | Zion | May 2016 | A1 |
20160263387 | Alinsod | Sep 2016 | A1 |
20160346561 | Ron Edoute | Dec 2016 | A1 |
20160346568 | Rockweiler | Dec 2016 | A1 |
20170014395 | Shalev et al. | May 2017 | A1 |
20170143997 | Rockweiler | May 2017 | A1 |
20170023946 | Shalev et al. | Aug 2017 | A1 |
20210002336 | Shalev et al. | Jan 2021 | A1 |
20220018438 | Shalev et al. | Jun 2022 | A1 |
20220022664 | Shalev et al. | Jul 2022 | A1 |
20220226646 | Shalev et al. | Jul 2022 | A1 |
20220226647 | Shalev et al. | Jul 2022 | A1 |
20220226648 | Shalev et al. | Jul 2022 | A1 |
20220226649 | Shalev et al. | Jul 2022 | A1 |
20220233851 | Shalev et al. | Jul 2022 | A1 |
20220028078 | Shalev et al. | Sep 2022 | A1 |
Number | Date | Country |
---|---|---|
1721010 | Jan 2006 | CN |
1568395 | Aug 2005 | EP |
2476460 | Jul 2012 | EP |
277882 | Sep 1927 | GB |
H119703 | Jan 1999 | JP |
3041670 | May 2000 | JP |
2001259047 | Sep 2001 | JP |
2003010145 | Jan 2003 | JP |
2003019215 | Jan 2003 | JP |
2004522497 | Jul 2004 | JP |
2007507317 | Mar 2007 | JP |
2006520247 | Sep 2007 | JP |
2008173231 | Jul 2008 | JP |
2008537896 | Oct 2008 | JP |
2008545462 | Dec 2008 | JP |
2012065693 | Apr 2012 | JP |
2153366 | Jul 2000 | RU |
2005131621 | Feb 2006 | RU |
0112089 | Feb 2001 | WO |
2008058452 | May 2008 | WO |
2009023568 | Feb 2009 | WO |
2012080394 | Jun 2012 | WO |
2015014811 | Feb 2015 | WO |
Entry |
---|
Supplementary European Search Report for Application No. EP10829624.5, dated Jan. 29, 2015. |
European Office Action for Application No. EP10829624.5, dated Feb. 20, 2015. |
Russian Office Action from Application No. 2012123457, dated Sep. 19, 2014. |
Japanese Office Action from Application No. 2012-538469, dated Sep. 16, 2014. |
Chinese Office Action from Application No. 201080051957.9, dated Jun. 4, 2014. |
Office Action for Australian Patent Application No. 2010317380 dated May 14, 2014. |
International Search Report for Application No. PCT/IL2010/000947, dated Apr. 5, 2011. |
Extended European Search Report—Corresponding European Application No. 16875059.4, dated Nov. 29, 2018, 9 pages. |
Godfrey, Sheila, “10 Electricity” In: “Principles and Practice of Electricall Epilation”, Oct. 16, 2001, Butterworth Heinemann, pp. 75-83. |
Y.Y. Dribnokhod, Cosmetology, Rostov-on-Don, “Fenix”, 2008, pp. 384-385. |
Number | Date | Country | |
---|---|---|---|
20160121112 A1 | May 2016 | US |
Number | Date | Country | |
---|---|---|---|
61261381 | Nov 2009 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13510062 | US | |
Child | 14970585 | US |